ArticleOncogene2021
Plectin is a regulator of prostate cancer growth and metastasis.
Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 58 citations in OpenAlex.
- Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer.Nature communications · 2026Article
- AI-guided design of plectin-1-targetedJournal of nanobiotechnology · 2026Article
- Plectin 1d Isoform as a Potential Regulator of Metastatic Progression in Papillary Thyroid Carcinoma.International journal of molecular sciences · 2026Article
- Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin.Molecular oncology · 2026Article
- Integrative phosphoproteomic network analysis identifies CAMK2D as a shared regulator of TPD52 family proteins in cancer.Protoplasma · 2026Article
- Plectin promotes an aggressive phenotype and represses cytotoxic T cell activity in pancreatic cancer.Frontiers in immunology · 2026Article
- PET-MR Examination in Diagnosing Bone Metastases in Prostate Cancer.Cancer management and research · 2026Article
- Coumarin Derivatives as Anticancer Agents: Mechanistic Landscape with an Emphasis on Breast Cancer.Molecules (Basel, Switzerland) · 2025Review
- Phosphorylation of plectin by Akt3 promotes triple-negative breast cancer cell invasive migration.iScience · 2025Article
- The Role of Plectin Dysregulation in Cancer: Recent Advances.Molecules (Basel, Switzerland) · 2025Review
- Correlation of plasma plectin levels with small intracranial aneurysms instability and prognosis.Neurosurgical review · 2025Article
- Rap2B drives tumorigenesis and progression of colorectal cancer through intestinal cytoskeleton remodeling.Cell death & disease · 2025Article
- Article
- Plectin, a novel regulator in migration, invasion and adhesion of ovarian cancer.Cell & bioscience · 2025Article
- Prediction of prognosis and immune response in lung adenocarcinoma based on mitophagy and lactate-related gene signatures.International journal of clinical oncology · 2025Article
- High matrix stiffness accelerates migration of hepatocellular carcinoma cells through the integrin β1-Plectin-F-actin axis.BMC biology · 2025Article
- Epiplakin expression dynamics during colon carcinogenesis: Correlation with proliferation.Biomolecules & biomedicine · 2024Article
- Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and PI3Kβ kinases.Journal of enzyme inhibition and medicinal chemistry · 2024Article
- Plectin: Dual Participation in Tumor Progression.Biomolecules · 2024Review
- A noncanonical E3 ubiquitin ligase RNF41-mediated MYO1C stability promotes prostate cancer metastasis by inducing actin remodeling.Oncogene · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Prostate cancer is responsible for over 30,000 US deaths annually, attributed largely to incurable metastatic disease. Here, we demonstrate that high levels of plectin are associated with localized and metastatic human prostate cancer when compared to benign prostate tissues. Knock-down of plectin inhibits prostate cancer cell growth and colony formation in vitro, and growth of prostate cancer xenografts in vivo. Plectin knock-down further impairs aggressive and invasive cellular behavior assessed by migration, invasion, and wound healing in vitro. Consistently, plectin knock-down cells have impaired metastatic colonization to distant sites including liver, lung, kidney, bone, and genitourinary system. Plectin knock-down inhibited number of metastases per organ, as well as decreased overall metastatic burden. To gain insights into the role of plectin in prostate cancer growth and metastasis, we performed proteomic analysis of prostate cancer plectin knock-down xenograft tissues. Gene set enrichment analysis shows an increase in levels of proteins involved with extracellular matrix and laminin interactions, and a decrease in levels of proteins regulating amino acid metabolism, cytoskeletal proteins, and cellular response to stress. Collectively these findings demonstrate that plectin is an important regulator of prostate cancer cell growth and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.